Breaking News Instant updates and real-time market news.

KMPH

KemPharm

$2.16

0.06 (2.86%)

16:17
10/30/18
10/30
16:17
10/30/18
16:17

KemPharm enters into licensing agreement with KVK Tech for Apadaz

KemPharm announced its entry into a definitive collaboration and license agreement with KVK Tech for the U.S. commercial rights of its FDA-approved prodrug product, Apadaz Under the terms of the agreement, KemPharm is eligible to receive up to an estimated $3.4M in pre-launch payments and certain cost reimbursements, including a $2.0M payment upon achievement of a specified milestone related to the initial formulary adoption of Apadaz, as well as an aggregate of up to $53M in milestone payments tied to specific net sales levels. In addition, net profits will be shared between KemPharm and KVK up to 50% based on achieving specified net sales levels. KVK has the exclusive right for all commercial, manufacturing, packaging and distribution activities for Apadaz in the U.S. and will be responsible for all regulatory and commercialization-related expenses. In addition, certain pre-launch expenses, including the costs of API and other materials for manufacturing, validation batches, inventory investments and other launch-specific costs will be shifted from KemPharm to KVK. Pre-launch activities that KemPharm and KVK will continue to collaborate on include outreach and plan adoption by pharmacy benefit managers and managed care organizations for the exclusive utilization of Apadaz as an alternative to currently available hydrocodone/acetaminophen products.

KMPH KemPharm
$2.16

0.06 (2.86%)

02/26/18
ADAM
02/26/18
NO CHANGE
Target $11
ADAM
Buy
KemPharm price target raised to $11 from $7 at Canaccord
Canaccord analyst Dewey Steadman raised his price target on KemPharm to $11 from $7 citing the FDA approval of Apadaz as a clear positive and a validation of the company's prodrug technology platform. He believes the company's strategy to position Apadaz as a generic to take advantage of the current market environment is a smart move. Steadman reiterated his Buy rating on KemPharm shares.
05/23/18
JANY
05/23/18
INITIATION
Target $17
JANY
Buy
KemPharm initiated with a Buy at Janney Capital
Janney Capital analyst Ken Trbovich initiated KemPharm with a Buy rating and $17 fair value estimate.
07/09/18
COWN
07/09/18
DOWNGRADE
COWN
Market Perform
KemPharm downgraded to Market Perform from Outperform at Cowen
Cowen analyst Ken Cacciatore downgraded KemPharm to Market Perform from Outperform citing uncertainty on the path forward for KP415 after the company announced top line results from a pivotal efficacy and safety clinical trial of the investigational attention-deficit/hyperactivity disorder product candidate.
09/20/18
OPCO
09/20/18
INITIATION
OPCO
Outperform
KemPharm assumed with an Outperform at Oppenheimer
Oppenheimer analyst Esther Rajavelu assumed coverage of KemPharm with an Outperform rating and an $11 price target, primarily due to a change in the firm's valuation methodology.

TODAY'S FREE FLY STORIES

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:45
02/19/19
02/19
07:45
02/19/19
07:45
Hot Stocks
Breaking Hot Stocks news story on Noble Midstream »

Noble Midstream sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

07:45
02/19/19
02/19
07:45
02/19/19
07:45
General news
Global Risks Ebb and Flow: »

Global Risks Ebb and…

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

07:44
02/19/19
02/19
07:44
02/19/19
07:44
Recommendations
XPO Logistics analyst commentary  »

XPO Logistics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:43
02/19/19
02/19
07:43
02/19/19
07:43
Hot Stocks
Noble Midstream sees FY19 capital budget $335M-$375M »

Noble Midstream's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:42
02/19/19
02/19
07:42
02/19/19
07:42
Hot Stocks
Noble Midstream sees adjusted EBITDA from partnership of at least $300M in 2020 »

Anticipates adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

CSX

CSX

$72.52

0.91 (1.27%)

07:41
02/19/19
02/19
07:41
02/19/19
07:41
Downgrade
CSX rating change  »

CSX downgraded to Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    May

HEXO

HEXO Corp

$5.57

0.17 (3.15%)

07:40
02/19/19
02/19
07:40
02/19/19
07:40
Initiation
HEXO Corp initiated  »

HEXO Corp initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

07:40
02/19/19
02/19
07:40
02/19/19
07:40
Downgrade
Windstream rating change  »

Windstream downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

AMSC

AMSC

$15.00

-0.8 (-5.06%)

07:40
02/19/19
02/19
07:40
02/19/19
07:40
Conference/Events
AMSC management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:40
02/19/19
02/19
07:40
02/19/19
07:40
Hot Stocks
Noble Midstream sees FY19 adjusted EBITDA $340M-$390M »

"Entering 2019, we…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

07:40
02/19/19
02/19
07:40
02/19/19
07:40
General news
Treasury Market Outlook: bond yields have dipped slightly lower amid risk-off flows »

Treasury Market Outlook:…

CEQP

Crestwood Equity

$32.82

-0.06 (-0.18%)

07:39
02/19/19
02/19
07:39
02/19/19
07:39
Earnings
Crestwood Equity sees FY19 net income $105M-$135M »

Sees FY 19 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

PODD

Insulet

$88.51

3.68 (4.34%)

07:38
02/19/19
02/19
07:38
02/19/19
07:38
Recommendations
Insulet analyst commentary  »

Insulet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

NWL

Newell Brands

$17.15

-4.55 (-20.97%)

07:38
02/19/19
02/19
07:38
02/19/19
07:38
Recommendations
Newell Brands analyst commentary  »

Newell Brands price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

CEQP

Crestwood Equity

$32.82

-0.06 (-0.18%)

07:38
02/19/19
02/19
07:38
02/19/19
07:38
Earnings
Crestwood Equity reports Q4 EPS 57c, may not compare to consensus 13c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

IRBT

iRobot

$119.34

4 (3.47%)

07:38
02/19/19
02/19
07:38
02/19/19
07:38
Downgrade
iRobot rating change  »

iRobot downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPC

W.P. Carey

$75.16

-0.02 (-0.03%)

07:36
02/19/19
02/19
07:36
02/19/19
07:36
Hot Stocks
W.P. Carey to invest $75M in food production facility in San Antonio »

W. P. Carey announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

EBAY

eBay

$36.59

0.28 (0.77%)

07:36
02/19/19
02/19
07:36
02/19/19
07:36
Recommendations
eBay analyst commentary  »

eBay January trends…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

MIDD

Middleby

$126.19

2.13 (1.72%)

07:36
02/19/19
02/19
07:36
02/19/19
07:36
Hot Stocks
Middleby announces retirement of CEO Selim Bassoul »

The Middleby Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEP

PepsiCo

07:36
02/19/19
02/19
07:36
02/19/19
07:36
Recommendations
PepsiCo analyst commentary  »

PepsiCo price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 18

    May

PATK

Patrick Industries

$47.06

2.01 (4.46%)

07:36
02/19/19
02/19
07:36
02/19/19
07:36
Recommendations
Patrick Industries analyst commentary  »

Patrick Industries price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SB

Safe Bulkers

$1.60

-0.01 (-0.62%)

07:35
02/19/19
02/19
07:35
02/19/19
07:35
Earnings
Safe Bulkers reports Q4 adj. EPS 7c, consensus 8c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NXRT

NexPoint Residential

$38.40

0.13 (0.34%)

07:35
02/19/19
02/19
07:35
02/19/19
07:35
Earnings
NexPoint Residential sees FY19 AFFO $2.16, consensus $2.24 »

Sees FY19 Same Store NOI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

DE

Deere

$158.99

-3.45 (-2.12%)

07:35
02/19/19
02/19
07:35
02/19/19
07:35
Recommendations
Deere analyst commentary  »

Too early to write off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 27

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

07:34
02/19/19
02/19
07:34
02/19/19
07:34
Hot Stocks
Biohaven Pharmaceutical's verdiperstat receives FDA orphan drug designation »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.